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Sepsis is the leading cause of death in critically ill and rapidness of identification is crucial to
prevent circulatory collapse, multisystem organ failure, and death. The International Surviving
Sepsis Guidelines supports the early implementation of empiric antimicrobial therapy. The
inappropriate use or overuse of antimicrobials results in increased antibiotic resistance, increased
healthcare costs, adverse drug events, and antibiotic-induced colitis. The use of a biomarker
specific to bacterial sepsis would allow the clinician to diagnose sepsis early and monitor
response to antimicrobial therapy, understanding the need to escalate, descalate, or discontinue
therapy. Procalcitonin has been proposed as such specific biomarker; able to differentiate sepsis
syndrome from systemic inflammatory response. Studies to date show mixed results regarding
the effectiveness of procalcitonin to identify, stage, and monitor response to treatment of sepsis.
Procalcitonin is not a gold standard in the diagnosis of sepsis; however, it is an important adjunct
to other physiological clinical markers.

The Use of Procalcitonin Monitoring in Critically Ill Adults for Early Identification
and Treatment of Sepsis
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Significance of the Problem
Sepsis is the leading cause of mortality in the critically ill. Rapidness in the identification
of sepsis is crucial to prevent progression to circulatory collapse, multisystem organ failure, and
death (Tang, Eslick, Craig, & McLean, 2007). The signs used for identification of sepsis such as
tachycardia, fever, tachypnea, and leukocytosis are all nonspecific and difficult to distinguish
from the clinical presentation of noninfectious conditions such as systemic inflammatory
response syndrome (SIRS); a very common condition in critical patients with burns, trauma, and
surgery (Tang et al., 2007). Barriers encountered in the clinical identification of sepsis
encompass the inability of many patients to describe their symptoms due to altered level of
consciousness, atypical appearance of clinical findings in the presence of immunological
incompetence, and the presence of other medications that alter the hemodynamic response
(Jensen et al., 2008).
To improve prognosis in the critically ill patient with sepsis, the International Surviving
Sepsis Campaign (ISSC) guidelines support implementing early antimicrobial therapy that is
active against the identified causative process (Jensen et al., 2011). Initial treatment for presumed
sepsis involves the use of empiric broad spectrum antibiotic therapy, which frequently results in
antibiotic overuse, antibiotic resistance, and increased healthcare costs (Nobre, Harbarth, Graf,
Rohner, & Pugin, 2008). In practice, 10 to 14 days of antibiotic treatment are common among
critical patients in the intensive care unit (ICU). If the length of antibiotic treatment is
unnecessary, it predisposes the patient to a higher risk of allergic reactions, drug adverse effects,
and antibiotic-induced colitis (Hochreiter et al., 2009).
An important consideration involves not only the early identification of sepsis and early
treatment, but the appropriate treatment for the causative pathogen. Theoretically, an ideal
biomarker would provide the clinician an early warning that the antimicrobial of choice is not
appropriate or effective (Jensen et al., 2011). Blood culture analysis poses considerable delays to
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diagnosis and results take 24 to 48 hours to yield results. Biological markers of inflammation
such as leukocytes or C-reactive protein (CRP) can be elevated for reasons other than sepsis and
are slowly released after progression of infection, which makes them unacceptable for rapid
identification and management of sepsis (Sinha, Desai, Mantri, & Kulkarni, 2011).
The ISSC guidelines of 2008 define sepsis as the presence of infection with systemic
manifestations including: temperature > 38.3 C or < 36 C, heart rate > 90 or 2 standard
deviations (SD) above the normal value for age, tachypnea, edema or positive fluid balance,
altered mental status, hyperglycemia, leukocytosis or leukopenia, normal WBC count with >
10% immature forms, CRP > 2 SD above normal, procalcitonin > 2 SD above normal, and
arterial hypotension. Severe sepsis is defined as the presence of sepsis along with tissue
hypoperfusion and organ dysfunction, evidenced by hypoxemia, acute lung injury, oliguria,
elevated creatinine, coagulopathy, ileus, hyperbilirubinemia, thrombocytopenia, and
hyperlactatemia. Finally, septic shock is defined as sepsis induced hypotension in spite of fluid
resuscitation (Dellinger et al., 2008).
Intervention and Intended Outcome
Serum procalcitonin (PCT) has been proposed as both a specific and sensitive early
biomarker in the presence of bacterial sepsis (Jensen et al., 2008). PCT is a 116-aminoacid
peptide and a precursor of calcium homeostasis. It is synthesized by thyroid C cells naturally;
however, in the presence of sepsis, it is extra-thyroidal in origin. PCT is theoretically able to
discern infectious from noninfectious causes of SIRS; additionally, PCT levels do not rise in
response to viral infections (Riedel, Melendez, An, Rosenbaum, & Zenilman, 2011; Tang et al.,
2007; Uzzan, Cohen, Nicolas, Cucherat, & Perret, 2006).
PCT is released in response to bacterial toxins and bacteria-specific proinflammatory
mediators such as IL-6, tumor necrosis factor, and interleukin 1b. PCT is released in the
bloodstream 2 to 6 hours after bacteria or its byproducts are present and levels plateau at 8 to 24
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hours. PCT levels in the postoperative patient only increase transiently for 12 to 24 hours, unlike
other markers such as leukocytes or CRP, which stay elevated for longer. Studies have reported
that following PCT levels, a biomarker that can mirror the severity of the disease, could prove
useful to evaluate antibiotic response. Decreased levels of PCT suggest an appropriate response
to antimicrobial therapy (Jensen et al., 2008; Schuetz et al., 2012).
Statement of the Clinical/PICO Question
Is the use of procalcitonin level monitoring in critically ill adults an effective tool for
early identification and treatment of sepsis?
Critical Analysis of the Evidence Related to the Clinical Question
Sinha et al. (2011) studied a group of 40 ICU patients to assess the usefulness of PCT as
a biomarker for sepsis in the critically ill adult. The authors found a statistically significant
correlation between the presence of sepsis and a PCT level between 0.5 and 2 ng/mL (p <
0.0001). PCT levels > 2 ng/ml had 86% sensitivity and 95% specificity, whereas levels of 0.5
ng/mL had a sensitivity of 90% and specificity of 84%. The study concluded that PCT levels
above 2 ng/mL are effective markers of sepsis. Falsely elevated levels of PCT were identified in
the presence of cardiogenic shock, trauma, major surgery, pancreatitis, and severe burns. The
study recommended the cutoff of 10 ng/mL to identify sepsis with coexisting cardiogenic shock.
Limitations of the study involved the small sample size and the lack of serial PCT measurements
(Sinha et al., 2011).
A prospective study by Ruiz-Alvarez et al. (2009) aimed to evaluate the diagnostic and
prognostic value of PCT in 103 critically ill patients with suspected sepsis in the ICU. Serum
PCT values were higher on patients with sepsis when compared to their non-infected cohort (p <
0.001) and levels correlated with the degree of severity of sepsis. The non-infected, sepsis,
severe sepsis, and septic shock groups had average PCT levels of 0.3, 1.1, 1.9, and 9.1 ng/mL
respectively (p < 0.001). PCT sensitivity was established at 83% and specificity at 62%. The best
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cutoff value for supporting the diagnosis of sepsis was 0.32 ng/mL. PCT values were
significantly and independently associated with the presence of infection in the multivariate
logistic regression model. PCT levels showed no statistical difference between survivors and
non-survivors; therefore, a prognostic value could not be established. The study concluded that
PCT was an accurate diagnostic parameter in differentiating SIRS from sepsis and PCT levels
could be used to categorize degrees of infection. The main limitation of the study is that a single
PCT level was collected on admission and correlation of one value to analyze outcome is
suboptimal (Ruiz-Alvarez et al., 2009).
Nobre et al. (2008) conducted a randomized controlled trial (RCT) of 79 patients using an
antimicrobial treatment algorithm based on daily fluctuation and evolution of serum PCT levels
to potentially shorten duration of antibiotic therapy in patients with severe sepsis and septic
shock. In the PCT group, patients’ antibiotic therapy was given according to PCT guidance and
control patients were treated under standard practice. All patients had baseline and daily PCT
levels performed for the first seven days. Every subject received antibiotic therapy based on the
suspected source of infection and local sensitivities and the antibiotic spectrum was narrowed
when possible. The investigators did not interfere with the duration of therapy in patients in the
control group but placed stopping rules for the intervention group based on serum PCT levels to
encourage discontinuation of antibiotics.
When PCT group patients had an admission baseline PCT level >1 ug/L, a decrease of
90% of baseline by day 5, or an absolute PCT value < 0.25 ug/L, investigators encouraged the
practitioners to discontinue antibiotics. For patients that had a baseline level <1 ug/L, providers
were encouraged to discontinue antibiotics when PCT levels were < 0.1 ug/L on day 3 and
clinical evaluation excluded presence of infection. The study found that the PCT group had a
lower median antibiotic duration of 6 versus 10 days (p= 0.003) and shorter median ICU length
of stay of 3 versus 5 days (p= 0.003) when compared to the control group. The average number
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of days alive without the use of antimicrobials for the PCT group was 17.4 ± 7.6 versus 13.6 ±
7.6 days for the control group (p= 0.04). The probability of having antimicrobial therapy
discontinued sooner for the PCT group was twofold higher (p= 0.009) (Nobre et al., 2008).
In summary, PCT showed accuracy in the initial diagnosis of sepsis. The potential
reduction in number of antibiotic days can lead to a decrease in cost, length of ICU stay, and
antibiotic exposure. Though the patients received daily PCT measurements in the clinical study
context, the frequency could be decreased to baseline, day 3, 5, and 6 to adhere to the algorithm
recommendations and contribute to cost effectiveness. This study was conducted in Switzerland
where the cost of 3 PCT measurements was $177. When compared to the savings established by
stopping the antibiotics earlier, plus a potential shorter ICU stay, this test could be established as
a cost-saving measure. There was no difference in 28-day mortality, clinical cure, or infection
relapse between both groups. Limitations of the study included the small sample size and the
exclusion of immunocompromised patients, those with complicated infections, or patients with
infections that are known to require prolonged antimicrobial therapy (Nobre et al., 2008).
The systematic review and metaanalysis by Uzzan et al. (2006) aimed to determine the
usefulness of PCT as a diagnostic marker for sepsis and septic shock in ICU, as well as in the
post operative and trauma settings. Twenty-five studies were reviewed with PCT sensitivities
ranging from 42 to 97% and specificities from 48 to 100%. The cutoff values of PCT-based
diagnosis of sepsis ranged between 0.6 to 5 ng/mL. PCT was found to have a global diagnostic
accuracy (DA) odds ratio (OR) of 15.7 with 95% confidence interval. In other words, PCT had
almost a sixteen-fold higher chance to be positive in infected than non-infected patients (p <
0.0001). If used as a rapid adjunct screening test, PCT can assist the clinician in identifying the
infected patient that should be given empiric antimicrobial therapy. “PCT is not a gold standard
for infection but may make this diagnosis easier especially in the emergency context of systemic
inflammation or shock” (p. 2001). Two limitations of this analysis should be considered. Some
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of the studies reviewed used the term sepsis as a mixture of sepsis, severe sepsis, and septic
shock; posing the risk of misclassification of study subjects. Additionally, the introduction of
excessive heterogeneity by merging studies dealing with different samples, settings, and
prognoses can be problematic, since diagnostic tests can have different accuracies at different
phases of disease (Uzzan et al., 2006).
Riedel et al. (2011) conducted a study to identify the usefulness of PCT testing in patients
in the emergency department (ED) as a predictive marker of bacteremia in febrile individuals. A
sample of 295 patients were grouped according to positive or negative blood cultures, and there
were significant differences in PCT levels between both groups (p= 0.00007). Statistical
differences in PCT levels were also found in patients with positive blood cultures for pathogens
when compared to patients with positive blood cultures due to contaminants (p= 0.01). The PCT
cutoff value relative to a positive blood culture for a pathogen was identified at 0.1475 ng/mL,
with a sensitivity of 75% and specificity of 78.9%.
In individuals without bacteremia or sepsis, PCT levels were 0.1 ng/mL or less. A value
of < 0.1 had 96.3% negative predictive value for bacteremia in ED patients when compared to
the use of blood cultures alone. Levels between 0.1 and 1 ng/mL could not predict either the
presence or absence of sepsis; therefore, blood cultures and other supportive clinical data to rule
out bacteremia were required. The study also supported the relationship between elevated levels
of PCT and number of blood culture sets positive for the pathogen detected. Typically more
positive culture sets suggest a more serious blood infection. However, one important limitation
to note is that only 16 patients in the study had positive blood cultures (Riedel et al., 2011).
Heper et al. (2006) conducted a study to establish the diagnostic value of distinguishing
sepsis from severe sepsis and septic shock in the first 72 hours post admission in 39 patients.
Additionally, the authors aimed to evaluate the trajectory of sepsis in survivors versus nonsurvivors, to establish the prognostic value of PCT monitoring. The diagnosis and grading of
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sepsis was based on the criteria from the American College of Chest Physicians and the Society
of Critical Care Medicine consensus. Patients were evaluated on admission, at 24, 48, and 72
hours and PCT levels were drawn at these times. When PCT levels were compared between the
different grades of sepsis, they were found to be significantly different; PCT levels were lower in
the sepsis group and higher in the severe sepsis group (p= 0.001, p= 0.009). For this study, the
severe sepsis and septic shock groups were combined under the category of severe sepsis.
Levels of PCT at the seventy-second hour were higher in patients who died compared to
those who recovered (p= 0.032). For the purpose of discrimination between sepsis and severe
sepsis, the PCT level of > 1.35 ng/ml had 88.9% sensitivity and 70% specificity. PCT levels
were found to be higher in the severe sepsis group at all times. It was difficult to establish an
exact PCT value for the diagnosis of sepsis. The study concluded that PCT levels increase as
sepsis worsens. The findings suggested that elevated PCT levels at 72 hours might suggest
refractory sepsis and possibly a poor outcome (Heper et al., 2006). The authors of this RCT did
not disclose limitations in their study; however, it is important to note that the severe sepsis and
septic shock groups were combined under the severe sepsis term; which complicates the
comparison of this study’s findings to others that classified infected patients under the standard
categories.
A randomized controlled trial by Hochreiter et al. (2009) aimed to establish the role of
serum PCT monitoring for guiding length of antimicrobial therapy in 110 surgical ICU patients.
Both the PCT-guided and control groups had PCT levels monitored daily and received antibiotic
treatment based on confirmed or suspected bacterial infections. For subjects in the PCT-guided
group, antibiotics were discontinued if the patients were clinically improved, had PCT levels <
1.0 ng/mL, or decreased by 25-35% from baseline value over three days. The study results
showed that in the PCT-guided group, antibiotic therapy was 5.9 ± 1.7 days shorter (p <0.001)
and the ICU length of stay was shorter with 15.5 ± 12.5 versus 17.7 ± 10.1 days in the control
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group (p = 0.046). The study concluded that PCT-guided therapy was able to shorten the length
of antibiotic treatment and ICU length of stay. No limitations of the study were presented;
however, one of the authors served as a consultant and had received payments from BRAHMS,
the manufacturer of PCT assays (Hochreiter et al., 2009).
Schuetz et al. (2012) conducted a systematic review of 14 RCTs regarding the use of
clinical algorithms using PCT levels in the management of sepsis and respiratory infections in
primary care, the ED, and ICUs. This review found a marked reduction in the use of antibiotics
in all settings; however, for the purposes of this particular paper, the author will concentrate on
the findings pertaining to critically ill adults. The algorithms varied between studies, but some
commonalities were established. First, in the most critical patients, PCT levels were used to
determine when to discontinue antibiotic therapy and not when to start treatment. Second, when
PCT levels trended down, there was an adequate correlation with resolution of bacterial
infection, allowing for early discontinuation of the antimicrobial agent before the typical course
was completed. Third, when PCT levels decreased to < 0.5 ug/L or by at least 80-90% from
baseline measurements, and the patient was clinically improved, it was recommended to stop
antimicrobial therapy. For the post operative critical patient, the threshold of •1
1 ug/L was used to
discontinue therapy. Fourth, if treatment was withheld initially, PCT levels were monitored in 6
to 12 hours. In the high risk acute patient in the ICU, algorithms called for empiric antimicrobial
therapy without delaying treatment for a PCT measurement (Schuetz et al., 2012).
This review suggested that the use of a PCT-guided algorithm for antimicrobial therapy is
effective at reducing rates of antibiotic use in patients with bronchitis, acute exacerbation of
COPD, pneumonia, and sepsis. Many of the studies reviewed were carried out in Europe, and
they should be repeated in the US to ascertain if this practice would be appropriate based on
population, practice, and different pathogenic makeup. An important limitation to consider is that
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in an attempt to minimize bias, the authors included a small number of RCTs in their review,
which could have excluded a large body of literature (Schuetz et al., 2012).
A systematic review and meta-analysis of seven PCT-guided algorithms suggested that
their use in the management of sepsis decreases antimicrobial duration of treatment and allows
for more antibiotic-free days. Three of the seven studies reported the total duration of
antimicrobial therapy and it was found to be lower in the PCT-guided group by approximately 4
days (p < 0.001) leading to almost 3 extra antibiotic-free days in the 28 day follow up (p <
0.00001). One study gathered information regarding cost effectiveness and found that PCT-based
strategies reduced the cost of antibiotic treatment by 17.8% (p < 0.01). Similar mortality,
hospital length of stay, number of ventilator-free days, and rates of superinfection or persistent
infection were comparable between the PCT-guided algorithm patients and the control groups
(Kopterides, Siempos, Tsangaris, Tsantes, & Armaganidis, 2010).
The review’s conclusions encouraged practitioners to tailor the treatment of sepsis with
the use of PCT as a biomarker instead of treating the patient based on empiric rules alone. It is
important to point out that mortality in critically ill patients is multifactorial and the adjustment
of one variable, such as early discontinuation of antibiotics, rarely results in decrease of overall
mortality. The findings need to validated by other RCTs, since studies reviewed here excluded
organisms that were difficult to treat needing prolonged antimicrobial therapy. Other limitations
include the small number of studies reviewed and the fact that not all the studies presented data
on the same outcomes making comparisons challenging. In conclusion, the use of PCT-guided
therapy is associated with reduced antibiotic exposure without compromising outcomes, but it is
still inadequately validated for antibiotic control (Kopterides et al., 2010).
Jensen et al. (2011) performed the Procalcitonin And Survival Study (PASS) which
aimed to establish whether early PCT monitoring and the use of an obligatory protocol for
antimicrobial management would result in efficient and appropriate choice of antimicrobial agent
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in the treatment of sepsis and improve 28-day survival in comparison to standard clinical
judgement. The study also aimed to identify whether the duration of organ failure and ICU
length of stay could be decreased. A total of 1200 adult patients who were judged to have
infection were included during the first 24 hours of their ICU admission. Subjects were excluded
if they had bilirubin levels > 40 mg/dL or triglycerides > 1000 mg/dL. Patients in the PCTguided group were given therapy directed by clinical guidelines and PCT levels with an
obligatory algorithm for intervention whereas the standard-of-care-only group was given
antimicrobial treatment based on clinical guidelines alone.
For the PCT-guided group, the ‘alert procalcitonin’ was used to prompt the clinician to
either start or increase antimicrobial therapy in the event of uncontrolled or refractory infection.
This alert was identified as PCT •1
1 ng/mL at baseline. For the control group, standard empiric
therapy was chosen according to the suspected pathogen and the potential site of infection. The
PCT-guided group had a longer median length of antibiotic therapy and were more likely to have
more frequent blood cultures drawn in the first 24 hours but they did not have more invasive
procedures or imaging studies (p <0.001). Twenty-eight day mortality analysis showed no
difference in survival between the ‘alert procalcitonin’ and the ‘non-alert procalcitonin’ group.
The time of death of non-survivors from both groups were comparable. Having an ‘alert
procalcitonin’ at baseline was an independent predictor of 28-day mortality and having frequent
alerts on the first five days was associated with increased risk of severe sepsis, septic shock,
persistent, and progressive infection. The PCT-guided group spent 65.5% days on the ventilator
compared to 60.7% for the standard-of-care group (p< .001). The average ICU length of stay was
longer in the PCT group compared to the control group, 6 versus 5 days (p = .004). Additionally,
the PCT-guided group had lower glomerular filtration rates and required dialysis and inotropic or
vasopressor therapy for longer. No difference was found in frequency of organ failure in either
group on day twenty-eight or day of discharge (Jensen et al., 2011).
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The study data suggested that the use of a PCT monitoring in real time and the algorithm
of therapeutic antimicrobial interventions did not improve survival, resulted in longer ICU length
of stay, and higher use of broad spectrum antimicrobials. There were also increased costs due to
the performance of the test itself, increased use of broad spectrum antibiotics, additional culture
samples, more ventilator and dialysis days, and increased ICU length of stay. The use of PCTguided algorithms suggested a harm effect based on the higher use of broad-spectrum
antimicrobials possibly causing more end-organ target damage. PCT sensitivity was established
at 59% using a cutoff of 1.0 ng/mL for diagnosis of sepsis, suggesting that this is not a reliable
test. Significant study limitations involve the nature of low microbial resistance in the Danish
hospitals where the study took place. Many patients had severe infections, but not all had blood
stream infections, which are the most powerful stipulations for PCT increase. The cutoff for
interventions of 1.0 ng/mL might have reduced the frequency of potential intervention in the
early phase of the disease This number was chosen based on previous studies that established
this as a cutoff for identifying sepsis in the critically ill as well as for determining mortality.
Lastly, the inclusion criteria for the study was not well defined and described as ‘broad’ (Jensen
et al., 2011).
A systematic review and meta-analysis of eighteen studies evaluated the accuracy of PCT
for sepsis diagnosis. The studies were grouped according to the Sackett and Haynes’
classification of training and validation sets to allow clinicians to evaluate the generalizability of
the studies’ findings. In the training set, the index test is developed in an ideal situation, whereas
the validation set is tested in a more realistic clinical context. Seventy-six percent of the patients
in this systematic review were included in the training set. The odds ratio (OR) and likelihood
ratio (LR) of PCT were consistently low. The pooled diagnostic OR for PCT was 7.79, which
suggests the test is unhelpful. PCT levels in the validation set showed greater variability and
lower accuracy (Tang et al., 2007).
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One considerable limitation of this review is the exclusion of all studies that assessed the
ability of PCT in the diagnosis of septic shock, because it was believed that this condition could
be diagnosed by clinical criteria alone. Tang et al. (2007) included a typical case mix of patients
seen in medical and surgical critical care units as well as emergency departments but excluded
all studies that were limited to restrictive patient groups such as burns, pancreatitis, or
meningitis. Therefore, the findings could be applicable to common clinical settings but not to
specific diseases. This systematic review did not evaluate the use of PCT as an adjunct bedside
assessment for diagnosis and disease management. In summary, PCT levels had low diagnostic
performance in the differentiation of SIRS and sepsis (Tang et al., 2007).

The Synthesis Answer to the Clinical Question
The literature review of 4 systematic reviews, 4 RCTs, and 3 prospective studies yielded
a wide range of results regarding the use of PCT for early diagnosis and treatment of sepsis. The
cutoff value for the identification of sepsis varied between 0.14 to 5 ug/mL, with the majority of
studies supporting 0.14 to 2 ug/mL. One study suggested PCT levels > 10 ug/mL to rule in sepsis
in the scenario of concurrent infection and cardiogenic shock. The diagnosis of sepsis was
supported with an average PCT level of 1.1 ug/mL, 1.35 ug/mL to 1.9 ug/mL for severe sepsis,
and > 9.1 ug/mL for septic shock. Additionally, PCT levels < 0.1 - 0.3 ug/mL generally excluded
sepsis, except for patients with high risk for infection, in which case a PCT level < 0.5 ug/mL
was necessary for exclusion. In the post surgical patient, a PCT level < 1 ug/mL excluded sepsis.
Discontinuation of antimicrobial therapy was encouraged with PCT levels < 0.5-1 ug/mL,
or a baseline PCT drop of 25-90%. The use of PCT-guided algorithms for antibiotic treatment
had mixed results. One systematic review found a decrease in antibiotic length of treatment,
increase in the number of antibiotic free days, and decrease in ICU length of stay. However, the
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PASS study found an increase in antibiotic days, hospital length of stay, ventilator days, dialysis
days, and lower glomerular filtration rates. In the analysis of prognosis and mortality, no
difference was found between the use of PCT-guided antibiotic algorithms versus empiric
treatment. There was no difference in frequency of organ failure, infection relapse, or clinical
course. There was not a statistically significant difference in PCT levels between survivors and
non survivors; however, it was noted that high PCT levels at 72 hours of treatment was an
indicator of refractory sepsis and poor outcome.
One systematic review strongly concluded that PCT values were not accurate in
differentiating SIRS from sepsis. Two RCTs found PCT to be a test low in diagnostic value with
a low sensitivity making it unreliable. Others studies found PCT to have modest contribution to
diagnosis of sepsis. One systematic review suggested that PCT levels had a sixteen-fold higher
chance to be positive in septic patients. Overall, PCT is not considered a gold standard diagnostic
tool for sepsis but could be useful as an adjunct of other clinical data.
Ten of the studies reviewed used the BRAHMS PCT monitoring systems from Germany.
Two studies used the rapid assay, one used the LIA, a manual assay, two studies used the
Lumitest, which is now known as LIA. Five studies used the Kryptor, the automated assay. Only
one study did not disclose its tool. Refer to the Appendix for the summary table.
Recommendations
Several recommendations can be implemented for the practicing provider caring for the
critically ill adult with suspected sepsis.
• The diagnosis of sepsis must be based on the current ISSC guidelines, which include the
use of PCT values to strengthen the diagnosis. PCT could be useful in an emergency setting to
rule in or rule out bacteremia. Most importantly, providers should never delay the initiation of
antimicrobial therapy while awaiting PCT results. If the clinical presentation and provider
suspicion is high enough for sepsis, starting the therapy promptly is crucial.
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• Providers should be cautious of PCT false positives in the presence of conditions such
as cardiogenic shock, pancreatitis, burns, and major surgery. The studies reviewed recommended
the PCT cutoff of 1 ug/mL for post operative patients and 10 ug/mL in the presence of suspected
sepsis coexisting with cardiogenic shock. The use of PCT values in other conditions are beyond
the scope of this paper.
• The use of PCT values in categorizing the stage and severity of sepsis can be a modest
tool for the assessment of a critically ill adult. PCT monitoring is not considered the gold
standard, yet there is evidence to support the use of baseline PCT and trends during antimicrobial
therapy to assess patients’ responsiveness to treatment. It would behoove the provider to use
PCT as an adjunct tool in conjunction to clinical presentation and provider expertise.
• PCT can be useful for antimicrobial decision making when preliminary blood cultures
are unavailable. In no way does the use of PCT monitoring exclude the usefulness of blood
cultures in this setting. Having a PCT level can be useful when preliminary blood cultures are
available and contamination is suspected. In this case, PCT levels would not rise and it can serve
as supportive evidence not to start or discontinue antibiotic therapy.
• Presently, the use of PCT levels cannot be used to predict outcome or mortality. In the
setting of critical care, there are numerous variables that contribute to mortality and survival. The
alteration of one component alone, such as stopping antibiotic therapy earlier when PCT levels
trend down, is unlikely to affect potential mortality or survival.
• Using the concept of ‘alert procalcitonin,’ PCT levels remaining > 1 ug/mL, could
potentially be an adequate model to alert the clinician to reevaluate the patient for occult,
refractory, or recurrent infections and consider alternate diagnoses or treatment modalities.
• The exclusion of sepsis should be considered with PCT levels < 0.25 ug/mL. However,
it is necessary to follow up PCT levels if the provider chooses not to start antimicrobial therapy.
Also, consider discontinuation of therapy if PCT levels decrease by 80-90% from baseline, in the
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presence of clinical improvement. In summary, the use of PCT for diagnosis of sepsis and
monitoring of effectiveness of treatment for sepsis is valuable as an adjunct tool to other clinical
markers.
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Appendix
PCT & Antibiotic
Initiation

PCT & Antibiotic
Discontinuation

PCT to r/o sepsis

Sinha et al. (2011)

> 2 ng/mL, >10 ng/mL
in cardiogenic shock

N/A

N/A

Ruiz-Alvarez et al.
(2009)

1.1 ng/mL sepsis
1.9 ng/mL severe sepsis
9.1 ng/mL septic shock

N/A

< 0.3 ng/mL

Nobre et al. (2008)

N/A

Baseline >1 ug/L,
90% baseline on day 5
or absolute < 0.25 ug/L
Baseline <1 ug/L, <0.1
on day 3

N/A

Uzzan et al. (2006)

0.6 - 5 ng/mL

N/A

N/A

Riedel et al. (2011)

0.1475 ng/mL

N/A

< 0.1 ng/mL

Heper et al. (2006)

>1.35 ng/mL to
differentiate sepsis
from severe sepsis

N/A

N/A

Hochreiter et al. (2009)

N/A

<1 ng/mL or 25-35%
of baseline

N/A

Schuetz et al. (2012)

N//A

<0.5 ug/L or 80-90%
of baseline
<1 ug/L in post op

N/A

Author/Year
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Kopteroides et al.
(2010)
Jensen et al. (2011)

Tang et al. (2007)
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PCT & Antibiotic
Initiation

PCT & Antibiotic
Discontinuation

PCT to r/o sepsis

N/A

N/A

N/A

>1 ug/mL

N/A

N/A

N/A

N/A

N/A

